Apnimed Trial Finds Utility in Viatom’s Pulse Oximeter Ring
Digital tool shows potential for longitudinal tracking of therapy response and patient-provider engagement.
Read More
Author: Sleep Review Staff
Rising Temps Linked with Increased OSA Burden
The burden of OSA has already risen an estimated 50% to 100% since 2000 due to climate change.
Read More
OSA Oral Drug Trial Success Positions Apnimed to File New Drug Application in 2026
AD109 met the primary endpoint, mean change in AHI at 26 weeks, across a broad range of people with mild, moderate, and severe OSA.
Read More
Hyoid Suspension for OSA ‘Effective and Non-Investigational’
A new position statement notes four decades of clinical research demonstrating the viability of hyoid suspension as an effective treatment for OSA.
Read More
First Orexin Agonist in Phase 3 Trials for Narcolepsy
A phase 3 readout is anticipated later this year.
Read More